表紙
市場調查報告書
商品編碼
1035793

光活化療法市場:光動力療法、光免疫療法、光熱療法:按目標疾病(頭頸癌、光角化症、黃體變性、息肉狀脈絡膜血管病)

Light Activated Therapies Market: Focus on Photodynamic Therapies, Photoimmunotherapies and Photothermal Therapies - Distribution by Target Indications (Head and Neck Cancer, Actinic Keratosis, Macular Degeneration, Polypoidal Choroidal Vasculopathy,

出版日期: | 出版商: Roots Analysis | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

視覺

根據世界衛生組織 (WHO) 的數據,全世界每年有 2 到 300 萬人患有各種形式的皮膚癌。雖然針對各種類型皮膚癌的安全有效治療方法的開發正在進行中,但迫切需要開發更具體、更有效的藥物和治療方法來應對這種複雜的疾病。我有。在這種情況下,能夠殺死體內病理細胞,同時最大限度地減少副作用的光活化療法(尤其是光動力療法、光免疫療法、光熱療法)是很有前景的。與化學療法和放射療法不同,光活化療法可以在不破壞周圍健康組織的情況下破壞癌細胞。因此,對於各種皮膚病,這種新療法與傳統療法相比具有多種優勢。

本報告調查了全球光活化療法市場,以及市場概況、光動力療法、光免疫療法和光熱療法的概述和作用機制,到 2030 年的市場預測以及針對的疾病。它提供了不同的趨勢,以及作為進入市場的公司的簡介。

目錄

第一章前言

  • 調查範圍
  • 調查方法
  • 重要問題得到解答
  • 本章概述

第 2 章執行摘要

第 3 章介紹

  • 光活化療法概述
  • 光活化療法的類型
  • 光活化療法的組成部分
    • 光敏劑
    • 光源和設備
  • 光活化療法的好處
  • 光免疫療法
    • 光免疫療法的作用機制
  • 光動力療法
    • 光動力療法的作用機制
    • 與光動力療法相關的好處和挑戰
  • 輕度熱療
    • 光熱的作用機制
  • 光動力療法和光熱療法的區別

第四章市場情況

  • 光活化療法:整體市場狀況
  • 光激活療法:開發商名單

第 5 章治療概況

  • 本章概述
  • 西妥昔單抗 Sarotalocan (R)
  • 光動力療法和 Alacare (R)
  • 光動力療法和 Ameluz (R)
  • 光動力療法和氨基乙□丙酸
  • 光動力療法和 Foscan (R) (Temoporfin)
  • 光動力療法和 FuMeiDa (R)(血泊芬)
  • 光動力療法和 Levulan Kerastick (R)
  • 光動力療法和 Metvixia (R) (Metvix)
  • 光動力療法和 Porfimer 鈉/Photofrin (R)
  • 光動力療法和 Verteporfin (R) (Visudyne)
  • TOOKAD (R) VTP

第6章臨床試驗分析

  • 分析研究方法及主要參數
  • 光活化療法:臨床試驗清單

第七章專利分析

  • 分析研究方法及主要參數
  • 光活化療法:專利分析

第8章市場規模和機會分析

  • 預測性研究方法和關鍵假設
  • 2021-2030 年光活化療法的總體市場
    • 光活化療法市場:按目標疾病分析
    • 光激活療法市場:主要參與者分析
    • 光活化療法市場:區域分析
    • 光活化療法:個別產品的銷售預測

第九章公司簡介

  • 本章概述
  • ADVANZ PHARMA
    • 公司簡介
    • 財務信息
    • 產品組合
  • 生物前沿
    • 公司簡介
    • 財務信息
    • 重要見解
    • 產品組合
    • 近期趨勢和未來前景
  • biolitec 製藥
    • 公司簡介
    • 產品組合
  • 盧茲廷
    • 公司簡介
    • 產品組合
    • 近期趨勢和未來前景
  • Nanospectra 生物科學
    • 公司簡介
    • 產品組合
    • 重要見解
    • 近期趨勢和未來前景
  • 光原子
    • 公司簡介
    • 產品組合
    • 重要見解
    • 近期趨勢和未來前景
  • 樂天醫療
    • 公司簡介
    • 財務信息
    • 產品組合
    • 重要見解
    • 近期趨勢和未來前景
  • Steba 生物技術公司
    • 公司簡介
    • 產品組合
    • 重要見解
    • 近期趨勢和未來前景
  • 熱□
    • 公司簡介
    • 財務信息
    • 產品組合
    • 重要見解
    • 近期趨勢和未來前景

第 10 章結論

第11章附錄1:匯總數據

目錄

Title:
Light Activated Therapies Market:
Focus on Photodynamic Therapies, Photoimmunotherapies and Photothermal Therapies - Distribution by Target Indications (Head and Neck Cancer, Actinic Keratosis, Macular Degeneration, Polypoidal Choroidal Vasculopathy, Cervical Intraepithelial Neoplasia, Bladder Cancer, Barrett's Esophagus, Gastric Cancer, Lung Cancer, Port-Wine Stain and Others), Key Players and Geographies (North America, Europe and Asia Pacific): Industry Trends and Global Forecasts, 2021-2030.

VISUALS

Overview:

According to the World Health Organization, in a year, around 2 million to 3 million individuals suffer from various forms of skin cancers, across the globe. This type of cancer account for 33% of all the diagnosed tumors, globally. It is also worth highlighting that one in every five Americans is likely to develop some form of skin cancer in their lifetime. Although efforts are being made to develop safe and effective drugs for the treatment of different types of skin cancer, there is still a pressing need for more specific and potent drugs / therapies to combat this complex clinical condition. Amidst the current initiatives to develop more targeted anti-cancer therapies, light activated therapies (specifically photodynamic therapies, photoimmunotherapies and photothermal therapies) have emerged as a promising alternative, owing to their capability to eradicate diseased cells from the body with minimal side effects. Unlike chemotherapy or radiotherapy, light activated therapies only destroy cancerous cells without damaging the surrounding healthy tissues. Therefore, this novel therapeutic approach has various advantages over conventional treatments for cancer and various skin diseases, such as acne, actinic keratosis, microvesicles, warts and others.

Over time, several pharmaceutical companies have undertaken various initiatives to develop effective photodynamic therapies / photoimmunotherapies against multiple target indications. At present, the pipeline features close to 130 candidates, and this value is anticipated to grow further in the foreseen future. Of these, more than 10 therapies, including ASP-1929 (Rakuten Medical), VISUDYNE® (Novartis), Metvix® (Galderma), PHOTOFRIN® (ADVANZ PHARMA), Ameluz® (Biofrontera) and LEVULAN® KERASTICK™ (Sun Pharma), have already been marketed. Further, over 635 patents related to light activated therapies have been filed / granted in the past three years, demonstrating the continued innovation in this domain. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in clinical trials of such therapy candidates. With multiple therapeutic leads in the mid to late stages of development (phase II and above) , we are led to believe that the light activated therapies market is likely to witness significant growth in the foreseen future.

Scope of the Report:

The "Light Activated Therapies Market: Focus on Photodynamic Therapies, Photoimmunotherapies and Photothermal Therapies, 2021-2030 - Distribution by Target Indications (Head and Neck Cancer, Actinic Keratosis, Macular Degeneration, Polypoidal Choroidal Vasculopathy, Cervical Intraepithelial Neoplasia, Bladder Cancer, Barrett's Esophagus, Gastric Cancer, Lung Cancer, Port-Wine Stain and Others), Key Players and Key Geographies (North America, Europe and Asia Pacific): Industry Trends and Global Forecasts" report features an extensive study of the current market landscape and the likely adoption of light activated therapies, over the next decade. The study features a detailed analysis of the key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of light activated therapies, with respect to current status of development (preclinical / discovery, phase I, phase I / II, phase II, phase II / III, phase III and approved) , type of light activated therapy (photodynamic therapy, photoimmunotherapy and photothermal therapy), therapeutic area (oncological disorders (solid tumor), dental disorders, skin disorders, oncological disorders (hematological cancer) and others) , type of photosensitive dye (methylene blue, phthalocyanine dye, indocyanine green, toluidine blue and phenothiazine hydrochloride), type of light (red light, blue light, infrared light, near-infrared light, visible light, ultraviolet light and daylight), target patient segment (children, adults and elderly patients), type of therapy (monotherapy and combination therapy) , type of developer (industry / non-industry) and popular target indications (periodontitis, actinic keratosis, basal cell carcinoma, head and neck cancer, lung cancer, cholangiocarcinoma, dental caries, squamous cell carcinoma, acne, bladder cancer, COVID-19, pancreatic cancer, prostate cancer and others) . In addition, the chapter includes analysis on the light activated therapy developer(s) based on various relevant parameters, including year of establishment, company size, location of headquarters and most active players (in terms of number of pipeline candidates) .
  • Detailed profiles of marketed and late stage (phase III) clinical products; each profile features an overview of the company, therapy overview, clinical development status, clinical trial endpoints, dosage information, key insights, clinical trial endpoints and estimated sales revenue (2021-2030).
  • An in-depth analysis of completed, ongoing and planned clinical studies of various light activated therapies based on relevant parameters, such as trial registration year, study design and trial phase, type of masking and type of intervention model, year and trial recruitment status, type of sponsor, most active industry and non-industry players (in terms of number of registered trials conducted), purpose of study, emerging focus area, location of trial, and key geographical regions.
  • An analysis of patents filed / granted related to light activated therapies, till 2021. The instances have been analyzed based on various relevant parameters, such as publication year, type of patent, patent age, geographical location, CPC symbols, emerging focus areas, leading patent assignees, leading industry and non-industry players (in terms of number of patents filed / granted) , patent benchmarking and valuation.
  • Elaborate profiles of companies (shortlisted based on phase of development of the lead drug) including brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for light activated therapies over the coming decade. Additionally, it features market size projections for the overall light activated therapies market, wherein both the current and upcoming opportunity is segmented across [A] target indications (head and neck cancer, actinic keratosis, macular degeneration, polypoidal choroidal vasculopathy, cervical intraepithelial neoplasia, bladder cancer, Barrett's esophagus, gastric cancer, lung cancer, port-wine stain and others) , [B] key players and [C] key geographies (North America, Europe, Asia Pacific) . In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry's evolution.

Key Questions Answered:

  • What are the prevalent R&D trends related to light activated therapies?
  • What are the key therapeutic areas for which light activated therapies are being / have been developed?
  • What are the key challenges faced by stakeholders related to manufacturing of light activated therapies?
  • Who are the leading industry and non-industry players engaged in the development of light activated therapies?
  • Across which geographies, extensive research related to light activated therapies is being conducted?
  • Which factors are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the light activated therapies market in the short to mid-term and long term.

Chapter 3 provides a general overview of light activated therapies. In this section, we have briefly discussed the advantages and general mechanism of action of various type of light activated therapies, including photoimmunotherapies, photodynamic therapies and photothermal therapies.

Chapter 4 includes detailed assessment on more than 125 light activated therapies that are currently approved or are in different stages of development. It features a comprehensive analysis of pipeline molecules with respect to the current status of development (preclinical / discovery, phase I, phase I / II, phase II, phase II / III, phase III and approved) , type of light activated therapy (photodynamic therapy, photoimmunotherapy and photothermal therapy) , therapeutic area (oncological disorders (solid tumor) , dental disorders, skin disorders, oncological disorders (hematological cancer) and others), type of photosensitive dye (methylene blue, phthalocyanine dye, indocyanine green, toluidine blue and phenothiazine hydrochloride) , type of light (red light, blue light, infrared light, near-infrared light, visible light, ultraviolet light and daylight), target patient segment (children, adults and elderly patients), type of therapy (monotherapy and combination therapy), type of developer (industry / non-industry) and popular target indications (periodontitis, actinic keratosis, basal cell carcinoma, head and neck cancer, lung cancer, cholangiocarcinoma, dental caries, squamous cell carcinoma, acne, bladder cancer, COVID-19, pancreatic cancer, prostate cancer and others) . In addition, the chapter includes information on the light activated therapy developer(s), highlighting their year of establishment, company size, and location of headquarters and most active players (in terms of number of pipeline candidates) .

Chapter 5 provides detailed profiles of marketed and late-stage clinical products (phase III). Each profile features an overview of the therapy, clinical development status, clinical trial endpoints, dosage information, key clinical trial results and estimated sales revenue (2021-2030).

Chapter 6 presents an in-depth analysis of completed, ongoing and planned clinical studies of various light activated therapies based on relevant parameters, such as trial registration year, study design and trial phase, type of masking and type of intervention model, year and trial recruitment status, type of sponsor, most active industry and non-industry players (in terms of number of registered trials conducted) , purpose of study, emerging focus area, location of trial, and key geographical regions

Chapter 7 provides analysis on over 635 patents filed / granted related to light activated therapies, till 2021. The instances have been analyzed based on various relevant parameters, such as publication year, type of patent, patent age, geographical location, CPC symbols, emerging focus areas, leading patent assignees, leading industry and non-industry players (in terms of number of patents filed / granted), patent benchmarking and valuation.

Chapter 8 presents an insightful market forecast analysis, highlighting the future potential of light activated therapies till the year 2030. In order to provide details on the future opportunity, our projections have been segmented across important market segments, namely [A] target indications (head and neck cancer, actinic keratosis, macular degeneration, polypoidal choroidal vasculopathy, cervical intraepithelial neoplasia, bladder cancer, Barrett's esophagus, gastric cancer, lung cancer, port-wine stain and others), [B] key players and [C] key geographies (North America, Europe, Asia Pacific and rest of the world).

Chapter 9 includes brief overview of the company (including information on their year of establishment, number of employees, location of headquarters and key executives) , financial information (if available), details on their respective product portfolio, recent developments and an informed future outlook.

Chapter 10 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 11 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 12 is an appendix, which contains the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Overview of Light Activated Therapies
  • 3.2. Types of Light Activated Therapies
  • 3.3. Components of Light Activated Therapies
    • 3.3.1. Photosensitizing Substance
    • 3.3.2. Light Source and Device
  • 3.4. Advantages of Light Activated Therapies
  • 3.5. Photoimmunotherapy
    • 3.5.1 Mechanism of Action of Photoimmunotherapies
  • 3.6. Photodynamic Therapy
    • 3.6.1. Mechanism of Action of Photodynamic Therapy
    • 3.6.2. Advantages and Challenges Associated with Photodynamic Therapy
  • 3.7. Photothermal Therapy
    • 3.7.1. Mechanism of Action of Photothermal Therapy
  • 3.8. Difference between Photodynamic and Photothermal Therapy

4. MARKET LANDSCAPE

  • 4.1. Light Activated Therapies: Overall Market Landscape
    • 4.1.1. Analysis by Current Status of Development
    • 4.1.2. Analysis by Type of Light Activated Therapy
    • 4.1.3. Analysis by Therapeutic Area
    • 4.1.4. Analysis by Current Status of Development and Therapeutic Area
    • 4.1.5. Analysis by Type of Photosensitive Dye
    • 4.1.6. Analysis by Type of Light
    • 4.1.7. Analysis by Target Patient Segment
    • 4.1.8. Analysis by Type of Therapy
    • 4.1.9. Analysis by Type of Developer
    • 4.1.10. Analysis by Popular Target Indications
    • 4.1.11. Leading Industry Players: Analysis by Number of Light Activated Therapies
    • 4.1.12. Leading Non-Industry Players: Analysis by Number of Light Activated Therapies
  • 4.2. Light Activated Therapies: List of Developers
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Regional Landscape of Developers

5. THERAPY PROFILES

  • 5.1. Chapter Overview
  • 5.2. Cetuximab Sarotalocan®
    • 5.2.1. Company Overview
    • 5.2.2. Therapy Overview
    • 5.2.3. Clinical Development Status
    • 5.2.4. Clinical Trial Endpoints
    • 5.2.5. Dosage Regimen
    • 5.2.6. Key Insights
    • 5.2.7. Estimated Sales Revenue
  • 5.3. Photodynamic Therapy and Alacare®
    • 5.3.1. Company Overview
    • 5.3.2. Therapy Overview
    • 5.3.3. Clinical Development Status
    • 5.3.4. Clinical Trial Endpoints
    • 5.3.5. Dosage Regimen
    • 5.3.6. Key Insights
    • 5.3.7. Estimated Sales Revenue
  • 5.4. Photodynamic Therapy and Ameluz®
    • 5.4.1. Company Overview
    • 5.4.2. Therapy Overview
    • 5.4.3. Clinical Development Status
    • 5.4.4. Dosage Regimen
    • 5.4.5. Key Insights
    • 5.4.6. Estimated Sales Revenue
  • 5.5. Photodynamic Therapy and Aminolevulinic Acid
    • 5.5.1. Company Overview
    • 5.5.2. Therapy Overview
    • 5.5.3. Clinical Development Status
    • 5.5.4. Key Insights
    • 5.5.5. Estimated Sales Revenue
  • 5.6. Photodynamic Therapy and Foscan® (Temoporfin)
    • 5.6.1. Company Overview
    • 5.6.2. Therapy Overview
    • 5.6.3. Clinical Development Status
    • 5.6.4. Clinical Trial Endpoints
    • 5.6.5. Dosage Regimen
    • 5.6.6. Key Insights
    • 5.6.7. Estimated Sales Revenue
  • 5.7. Photodynamic Therapy and FuMeiDa® (Hemoporfin)
    • 5.7.1. Company Overview
    • 5.7.2. Therapy Overview
    • 5.7.3. Clinical Development Status
    • 5.7.4. Clinical Trial Endpoints
    • 5.7.5. Dosage Regimen
    • 5.7.6. Key Insights
    • 5.7.7. Estimated Sales Revenue
  • 5.8. Photodynamic Therapy and Levulan Kerastick®
    • 5.8.1. Company Overview
    • 5.8.2. Therapy Overview
    • 5.8.3. Clinical Development Status
    • 5.8.4. Dosage Regimen
    • 5.8.5. Key Insights
    • 5.8.6. Estimated Sales Revenue
  • 5.9. Photodynamic Therapy and Metvixia® (Metvix)
    • 5.9.1. Company Overview
    • 5.9.2. Therapy Overview
    • 5.9.3. Clinical Development Status
    • 5.9.4. Clinical Trial Endpoints
    • 5.9.5. Dosage Regimen
    • 5.9.6. Key Insights
    • 5.9.7. Estimated Sales Revenue
  • 5.10. Photodynamic Therapy and Porfimer Sodium / Photofrin®
    • 5.10.1. Company Overview
    • 5.10.2. Therapy Overview
    • 5.10.3. Clinical Development Status
    • 5.10.4. Clinical Trial Endpoints
    • 5.10.5. Dosage Regimen
    • 5.10.6. Estimated Sales Revenue
  • 5.11. Photodynamic Therapy and Verteporfin® (Visudyne)
    • 5.11.1. Company Overview
    • 5.11.2. Therapy Overview
    • 5.11.3. Clinical Development Status
    • 5.11.4. Clinical Trial Endpoints
    • 5.11.5. Dosage Regimen
    • 5.11.6. Key Insights
    • 5.11.7. Estimated Sales Revenue
  • 5.12. TOOKAD® VTP
    • 5.12.1. Company Overview
    • 5.12.2. Therapy Overview
    • 5.12.3. Clinical Development Status
    • 5.12.4. Clinical Trial Endpoints
    • 5.12.5. Dosage Regimen
    • 5.12.6. Key Insights
    • 5.12.7. Estimated Sales Revenue

6. CLINICAL TRIAL ANALYSIS

  • 6.1. Analysis Methodology and Key Parameters
  • 6.2. Light Activated Therapies: List of Clinical Trials
    • 6.3.1. Analysis by Trial Registration Year
    • 6.3.2. Analysis by Study Design and Trial Phase
    • 6.3.3. Analysis by Type of Masking and Intervention Model
    • 6.3.4. Analysis by Year and Trial Recruitment Status
    • 6.3.5. Analysis by Type of Sponsor
    • 6.3.6. Leading Industry Players: Analysis by Number of Trials Registered
    • 6.3.7. Leading Non-Industry Players: Analysis by Number of Trials Registered
    • 6.3.8. Analysis by Purpose of Study
    • 6.3.9. Analysis by Trial Recruitment Status
    • 6.3.10. Analysis by Emerging Focus Area
    • 6.3.11. Analysis by Location of Trial
    • 6.3.12. Analysis by Trial Status and Geography

7. PATENT ANALYSIS

  • 7.1. Analysis Methodology and Key Parameters
  • 7.2. Light Activated Therapies: Patent Analysis
    • 7.2.1. Analysis by Publication Year
    • 7.2.2. Analysis by Type of Patent
    • 7.2.3. Analysis by Patent Age
    • 7.2.4. Analysis by Geographical Location
    • 7.2.5. Analysis by Emerging Focus Areas
    • 7.2.6. Leading Patent Assignees: Analysis by Number of Patents
    • 7.2.7. Analysis by Type of Players
    • 7.2.8. Leading Industry Players: Analysis by Number of Patents
    • 7.2.9. Leading Non-Industry Players: Analysis by Number of Patents
    • 7.2.10. Analysis by CPC Symbols
    • 7.2.11. Light Activated Therapies: Patent Benchmarking Analysis
    • 7.2.12. Light Activated Therapies: Patent Valuation Analysis

8. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 8.1. Forecast Methodology and Key Assumptions
  • 8.2. Overall Light Activated Therapies Market, 2021-2030
    • 8.2.1. Light Activated Therapies Market: Analysis by Target Indication
    • 8.2.2. Light Activated Therapies Market: Analysis by Key Players
    • 8.2.3. Light Activated Therapies Market: Analysis by Geography
    • 8.2.4. Light Activated Therapies: Forecast of Individual Product Sales
      • 8.2.4.1. Cetuximab Sarotalocan® (Rakuten Medical): Estimated Sales Revenues
      • 8.2.4.2. Photodynamic Therapy and Alacare® (medec): Estimated Sales Revenues
      • 8.2.4.3. Photodynamic Therapy and Ameluz® (Biofrontera): Estimated SalesRevenues
      • 8.2.4.4. Photodynamic Therapy and Aminolevulinic Acid (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical): Estimated Sales Revenues
      • 8.2.4.5. Photodynamic Therapy and Foscan® (biolitec Pharma): Estimated SalesRevenues
      • 8.2.4.6. Photodynamic Therapy and FuMeiDa® (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical): Estimated Sales Revenues
      • 8.2.4.7. Photodynamic Therapy and Levulan Kerastick® (Sun Pharmaceuticals):Estimated Sales Revenues
      • 8.2.4.8. Photodynamic Therapy and Metvixia® / Metvix® (Galderma): Estimated SalesRevenues
      • 8.2.4.9. Photodynamic Therapy and Porfimer Sodium / Photofrin® (ADVANZPHARMA): Estimated Sales Revenues
      • 8.2.4.10. Photodynamic Therapy and Verteporfin® / Visudyne® (Novartis): EstimatedSales Revenues
      • 8.2.4.11. Photodynamic Therapy and TLD-1433 (Theralase): Estimated Sales Revenues
      • 8.2.4.12. TOOKAD® VTP (Steba biotech): Estimated Sales Revenues

9. COMPANY PROFILES

  • 9.1. Chapter Overview
  • 9.2. ADVANZ PHARMA
    • 9.2.1. Company Overview
    • 9.2.2. Financial Information
    • 9.2.3. Product Portfolio
  • 9.3. Biofrontera
    • 9.3.1. Company Overview
    • 9.3.2. Financial Information
    • 9.3.3. Key Insights
    • 9.3.4. Product Portfolio
    • 9.3.5. Recent Developments and Future Outlook
  • 9.4. biolitec Pharma
    • 9.4.1. Company Overview
    • 9.4.3. Product Portfolio
  • 9.5. Luzitin
    • 9.5.1. Company Overview
    • 9.5.2. Product Portfolio
    • 9.5.3. Recent Developments and Future Outlook
  • 9.6. Nanospectra Biosciences
    • 9.6.1. Company Overview
    • 9.6.2. Product Portfolio
    • 9.6.3. Key Insights
    • 9.6.4. Recent Developments and Future Outlook
  • 9.7. photoatomic
    • 9.7.1. Company Overview
    • 9.7.2. Product Portfolio
    • 9.7.3. Key Insights
    • 9.7.4. Recent Developments and Future Outlook
  • 9.8. Rakuten Medical
    • 9.8.1. Company Overview
    • 9.8.2. Financial Information
    • 9.8.3. Product Portfolio
    • 9.8.4. Key Insights
    • 9.8.5. Recent Developments and Future Outlook
  • 9.9. Steba biotech
    • 9.9.1. Company Overview
    • 9.9.2. Product Portfolio
    • 9.9.3. Key Insights
    • 9.9.4. Recent Developments and Future Outlook
  • 9.10. Theralase
    • 9.10.1. Company Overview
    • 9.10.2. Financial Information
    • 9.10.3. Product Portfolio
    • 9.10.4. Key Insights
    • 9.10.5. Recent Developments and Future Outlook

10. CONCLUSION

11. APPENDIX 1: TABULATED DATA

List Of Figures

  • Figure 2.1 Executive Summary: Overall Market Landscape
  • Figure 2.2 Executive Summary: Clinical Trial Analysis
  • Figure 2.3 Executive Summary: Patent Analysis
  • Figure 2.4 Executive Summary: Market Forecast
  • Figure 3.1 Types of Light Activated Therapies
  • Figure 3.2 Mechanism of Action of Photoimmunotherapies
  • Figure 3.3 Mechanism of Action of Photodynamic Therapy
  • Figure 3.4 Advantages and Challenges associated with Photodynamic Therapy
  • Figure 3.5 Mechanism of Action of Photothermal Therapy
  • Figure 4.1 Light Activated Therapies: Distribution by Current Status of Development
  • Figure 4.2 Light Activated Therapies: Distribution by Type of Light Activated Therapy
  • Figure 4.3 Light Activated Therapies: Distribution by Therapeutic Area
  • Figure 4.4 Light Activated Therapies: Distribution by Current Status of Development andTherapeutic Area
  • Figure 4.5 Light Activated Therapies: Distribution by Photosensitive Dye
  • Figure 4.6 Light Activated Therapies: Distribution by Type of Light
  • Figure 4.7 Light Activated Therapies: Distribution by Target Patient Segment
  • Figure 4.8 Light Activated Therapies: Distribution by Type of Therapy
  • Figure 4.9 Light Activated Therapies: Distribution by Type of Developer
  • Figure 4.10 Light Activated Therapies: Distribution by Popular Target Indications
  • Figure 4.11 Leading Industry Players: Distribution by Number of Light Activated Therapies
  • Figure 4.12 Leading Non-Industry Players: Distribution by Number of Light Activated Therapies
  • Figure 4.13 Light Activated Therapy Developers: Distribution by Year of Establishment
  • Figure 4.14 Light Activated Therapy Developers: Distribution by Company Size
  • Figure 4.15 Light Activated Therapy Developers: Distribution by Location of Headquarters
  • Figure 4.16 Light Activated Therapy Developers: Regional Landscape
  • Figure 5.1 Cetuximab Sarotalocan®: Estimated sales revenue
  • Figure 5.2 Photodynamic Therapy and Alacare®: Estimated sales revenue
  • Figure 5.3 Photodynamic Therapy and Ameluz®: Estimated sales revenue
  • Figure 5.4 Photodynamic Therapy and Aminolevulinic Acid: Estimated salesrevenue
  • Figure 5.5 Photodynamic Therapy and Foscan® (Temoporfin): Estimated salesrevenue
  • Figure 5.6 Photodynamic Therapy and FuMeiDa® (Hemoporfin): Estimated salesrevenue
  • Figure 5.7 Photodynamic Therapy and Levulan Kerastick®: Estimated sales
  • Figure 5.8 Photodynamic Therapy and Metvixia® (Metvix): Estimated sales
  • Figure 5.9 Photodynamic Therapy and Porfimer Sodium / Photofrin®: Estimatedsales revenue
  • Figure 5.10 Photodynamic Therapy and Verteporfin® (Visudyne): Estimated salesrevenue
  • Figure 5.12 Photodynamic Therapy and TOOKAD® VTP: Estimated sales revenue
  • Figure 6.1 Clinical Trial Analysis: Distribution by Trial Registration Year
  • Figure 6.2 Clinical Trial Analysis: Distribution by Study Design and Trial Phase
  • Figure 6.3 Clinical Trial Analysis: Distribution by Type of Masking and Intervention Model
  • Figure 6.4 Clinical Trial Analysis: Distribution by Year and Trial Recruitment Status
  • Figure 6.5 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Figure 6.6 Leading Industry Players: Distribution by Number of Trials Registered
  • Figure 6.7 Leading Non-Industry Players: Distribution by Number of Trials Registered
  • Figure 6.8 Clinical Trial Analysis: Distribution by Purpose of Study
  • Figure 6.9 Clinical Trial Analysis: Distribution by Trial Recruitment Status
  • Figure 6.10 Clinical Trial Analysis: Distribution by Emerging Focus Area
  • Figure 6.11 Clinical Trial Analysis: Distribution by Location of Trial(s)
  • Figure 6.12 Clinical Trial Analysis: Distribution by Trial Status and Geography
  • Figure 7.1 Patent Analysis: Distribution by Publication Year
  • Figure 7.2 Patent Analysis: Distribution by Type of Patent
  • Figure 7.3 Patent Analysis: Distribution by Patent Age
  • Figure 7.4 Patent Analysis: Distribution by Geographical Location
  • Figure 7.5 Patent Analysis: Distribution by Emerging Focus Areas
  • Figure 7.6 Leading Patent Assignees: Distribution by Number of Patents
  • Figure 7.7 Leading Industry Players: Distribution by Number of Patents
  • Figure 7.8 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 7.9 Patent Analysis: Distribution by CPC Symbols
  • Figure 7.10 Light Activated Therapies: Patent Benchmarking
  • Figure 7.11 Light Activated Therapies: Patent Valuation
  • Figure 8.1 Light Activated Therapies Market, 2021-2030 (USD Million)
  • Figure 8.2 Light Activated Therapies Market, 2021-2030: Distribution by Target Indication (USD Million)
  • Figure 8.3 Light Activated Therapies Market, 2021-2030: Distribution by Key Players (USD Million)
  • Figure 8.4 Light Activated Therapies Market, 2021-2030: Distribution by Geography (USD Million)
  • Figure 8.5 Cetuximab Sarotalocan® (Rakuten Medical): Sales Forecast, 2021-2030 (USD Million)
  • Figure 8.6 Photodynamic Therapy and Alacare® (medec): Sales Forecast, 2021-2030(USD Million)
  • Figure 8.7 Photodynamic Therapy and Ameluz® (Biofrontera): Sales Forecast, 2021-2030(USD Million)
  • Figure 8.8 Photodynamic Therapy and Aminolevulinic Acid (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical): Sales Forecast, 2021-2030
  • Figure 8.9 Photodynamic Therapy and Foscan® (Temoporfin) (biolitec Pharma): SalesForecast, 2021-2030 (USD Million)
  • Figure 8.10 Photodynamic Therapy and FuMeiDa® (Hemoporfin) (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical): Sales Forecast, 2021-2030 (USD Million)
  • Figure 8.11 Photodynamic Therapy and Levulan Kerastick® (Sun Pharmaceuticals): SalesForecast, 2021-2030 (USD Million)
  • Figure 8.12 Photodynamic Therapy and Metvixia® (Metvix) (Galderma): Sales Forecast,2021-2030 (USD Million)
  • Figure 8.13 Photodynamic Therapy and Porfimer Sodium / Photofrin® (ADVANZPHARMA): Sales Forecast, 2021-2030 (USD Million)
  • Figure 8.14 Photodynamic Therapy and Verteporfin® (Visudyne) (Novartis): SalesForecast, 2021-2030 (USD Million)
  • Figure 8.15 Photodynamic Therapy and TLD-1433 (Theralase): Sales Forecast, 2021-2030(USD Million)
  • Figure 8.16 Photodynamic Therapy and TOOKAD® VTP (Steba biotech): Sales Forecast,2021-2030 (USD Million)
  • Figure 9.1 ADVANZ PHARMA: Annual Revenues, 2016-H1 2021 (USD Billion)
  • Figure 9.2 Biofrontera: Annual Revenues, 2016-H1 2021 (USD Billion)
  • Figure 9.6 Rakuten Medical: Annual Revenues, 2016-H1 2021 (USD Billion)
  • Figure 9.7 Theralase: Annual Revenues, 2016-H1 2021 (USD Billion)
  • Figure 10.1 Concluding Remarks: Overall Market Landscape
  • Figure 10.2 Concluding Remarks: Clinical Trial Analysis
  • Figure 10.3 Concluding Remarks: Patent Analysis
  • Figure 10.4 Concluding Remarks: Market Forecast

List Of Tables

  • Table 4.1 Light Activated Therapies: Drug Pipeline
  • Table 4.2 Light Activated Therapies: List of Developers
  • Table 5.1 Cetuximab Sarotalocan®: Clinical Developmental Status
  • Table 5.2 Cetuximab Sarotalocan®: Clinical Trial Endpoints
  • Table 5.3 Cetuximab Sarotalocan®: Dosage Regimen
  • Table 5.4 Cetuximab Sarotalocan®: Key Insights
  • Table 5.5 Photodynamic Therapy and Alacare®: Clinical Developmental Status
  • Table 5.6 Photodynamic Therapy and Alacare®: Clinical Trial Endpoints
  • Table 5.7 Photodynamic Therapy and Alacare®: Dosage Regimen
  • Table 5.8 Photodynamic Therapy and Alacare®: Key Insights
  • Table 5.9 Photodynamic Therapy and Ameluz®: Clinical Developmental Status
  • Table 5.10 Photodynamic Therapy and Ameluz®: Clinical Trial Endpoints
  • Table 5.11 Photodynamic Therapy and Ameluz®: Dosage Regimen
  • Table 5.12 Photodynamic Therapy and Ameluz®: Key Insights
  • Table 5.13 Photodynamic Therapy and Aminolevulinic Acid: Clinical DevelopmentalStatus
  • Table 5.14 Photodynamic Therapy and Aminolevulinic Acid: Key Insights
  • Table 5.15 Photodynamic Therapy and Foscan® (Temoporfin): Clinical DevelopmentalStatus
  • Table 5.16 Photodynamic Therapy and Foscan® (Temoporfin): Clinical Trial Endpoints
  • Table 5.17 Photodynamic Therapy and Foscan® (Temoporfin): Dosage Regimen
  • Table 5.18 Photodynamic Therapy and Foscan® (Temoporfin): Key Insights
  • Table 5.19 Photodynamic Therapy and FuMeiDa® (Hemoporfin): Clinical DevelopmentalStatus
  • Table 5.20 Photodynamic Therapy and FuMeiDa® (Hemoporfin): Clinical Trial Endpoints
  • Table 5.21 Photodynamic Therapy and FuMeiDa® (Hemoporfin): Dosage Regimen
  • Table 5.22 Photodynamic Therapy and FuMeiDa® (Hemoporfin): Key Insights
  • Table 5.23 Photodynamic Therapy and Levulan Kerastick®: Clinical DevelopmentalStatus
  • Table 5.24 Photodynamic Therapy and Levulan Kerastick®: Clinical Trial Endpoints
  • Table 5.25 Photodynamic Therapy and Levulan Kerastick®: Dosage Regimen
  • Table 5.26 Photodynamic Therapy and Levulan Kerastick®: Key Insights
  • Table 5.27 Photodynamic Therapy and Metvixia® (Metvix): Clinical DevelopmentalStatus
  • Table 5.28 Photodynamic Therapy and Metvixia® (Metvix): Clinical Trial Endpoints
  • Table 5.29 Photodynamic Therapy and Metvixia® (Metvix): Dosage Regimen
  • Table 5.30 Photodynamic Therapy and Metvixia® (Metvix): Key Insights
  • Table 5.31 Photodynamic Therapy and Porfimer Sodium / Photofrin®: ClinicalDevelopmental Status
  • Table 5.32 Photodynamic Therapy and Porfimer Sodium / Photofrin®: Clinical Trial Endpoints
  • Table 5.33 Photodynamic Therapy and Porfimer Sodium / Photofrin®: Dosage Regimen
  • Table 5.34 Photodynamic Therapy and Verteporfin® (Visudyne): Clinical DevelopmentalStatus
  • Table 5.35 Photodynamic Therapy and Verteporfin® (Visudyne): Clinical Trial Endpoints
  • Table 5.36 Photodynamic Therapy and Verteporfin® (Visudyne): Dosage Regimen
  • Table 5.37 Photodynamic Therapy and Verteporfin® (Visudyne): Key Insights
  • Table 5.38 Photodynamic Therapy and TOOKAD® VTP: Clinical Developmental Status
  • Table 5.39 Photodynamic Therapy and TOOKAD® VTP: Clinical Trial Endpoints
  • Table 5.40 Photodynamic Therapy and TOOKAD® VTP: Dosage Regimen
  • Table 5.41 Photodynamic Therapy and TOOKAD® VTP: Key Insights
  • Table 6.1 Light Activated Therapies: List of Clinical Trials
  • Table 7.1 Light Activated Therapies: List of Patents
  • Table 9.1 ADVANZ PHARMA: Product Portfolio
  • Table 9.2 Biofrontera: Product Portfolio
  • Table 9.3 Biofrontera: Recent Developments and Future Outlook
  • Table 9.4 biolitec Pharma: Product Portfolio
  • Table 9.5 Luzitin: Product Portfolio
  • Table 9.6 Luzitin: Recent Developments and Future Outlook
  • Table 9.7 Nanospectra Biosciences: Product Portfolio
  • Table 9.8 Nanospectra Biosciences: Recent Developments and Future Outlook
  • Table 9.9 photoatomic: Product Portfolio
  • Table 9.10 photoatomic: Recent Developments and Future Outlook
  • Table 9.11 Rakuten Medical: Product Portfolio
  • Table 9.12 Rakuten Medical: Recent Developments and Future Outlook
  • Table 9.13 Theralase: Product Portfolio
  • Table 9.14 Theralase: Recent Developments and Future Outlook
  • Table 9.15 Steba biotech: Product Portfolio
  • Table 9.16 Steba biotech: Recent Developments and Future Outlook
  • Table 11.1 Light Activated Therapies: Distribution by Current Status of Development
  • Table 11.2 Light Activated Therapies: Distribution by Type of Light Activated Therapy
  • Table 11.3 Light Activated Therapies: Distribution by Therapeutic Area
  • Table 11.4 Light Activated Therapies: Distribution by Current Status of Development andTherapeutic Area
  • Table 11.5 Light Activated Therapies: Distribution by Photosensitive Dye
  • Table 11.6 Light Activated Therapies: Distribution by Type of Light
  • Table 11.7 Light Activated Therapies: Distribution by Target Patient Segment
  • Table 11.8 Light Activated Therapies: Distribution by Type of Therapy
  • Table 11.9 Light Activated Therapies: Distribution by Type of Developer
  • Table 11.10 Light Activated Therapies: Distribution by Popular Target Indication
  • Table 11.11 Leading Industry Players: Distribution by Number of Light Activated Therapies
  • Table 11.12 Leading Non-Industry Players: Distribution by Number of Light Activated Therapies
  • Table 11.13 Light Activated Therapy Developers: Distribution by Year of Establishment
  • Table 11.14 Light Activated Therapy Developers: Distribution by Company Size
  • Table 11.15 Light Activated Therapy Developers: Distribution by Location of Headquarters
  • Table 11.16 Light Activated Therapy Developers: Regional Landscape
  • Table 11.17 Clinical Trial Analysis: Distribution by Trial Registration Year
  • Table 11.18 Clinical Trial Analysis: Distribution by Study Design and Trial Phase
  • Table 11.29 Clinical Trial Analysis: Distribution by Type of Masking and Intervention Model
  • Table 11.30 Clinical Trial Analysis: Distribution by Year and Trial Recruitment Status
  • Table 11.31 Clinical Trial Analysis: Distribution by Type of Sponsor(s)
  • Table 11.32 Leading Industry Players: Distribution by Number of Trials Registered
  • Table 11.33 Leading Non-Industry Players: Distribution by Number of Trials Registered
  • Table 11.34 Clinical Trial Analysis: Distribution by Trial Recruitment Status
  • Table 11.34 Clinical Trial Analysis: Distribution by Purpose of Study
  • Table 11.35 Clinical Trial Analysis: Distribution by Emerging Focus Areas
  • Table 11.36 Clinical Trial Analysis: Distribution by Location of Trial(s)
  • Table 11.37 Clinical Trial Analysis: Distribution by Trial Status and Geography
  • Table 11.38 Patent Analysis: Distribution by Publication Year
  • Table 11.39 Patent Analysis: Distribution by Type of Patent
  • Table 11.40 Patent Analysis: Distribution by Patent Age
  • Table 11.41 Patent Analysis: Distribution by Geographical Location
  • Table 11.42 Patent Analysis: Distribution by Emerging Focus Areas
  • Table 11.43 Leading Patent Assignees: Distribution by Number of Patents
  • Table 11.44 Leading Industry Players: Distribution by Number of Patents
  • Table 11.45 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 11.46 Patent Analysis: Distribution by CPC Symbols
  • Table 11.47 Light Activated Therapies: Patent Benchmarking
  • Table 11.48 Light Activated Therapies: Patent Valuation
  • Table 11.49 Light Activated Therapies Market, 2021-2030 (USD Million)
  • Table 11.50 Light Activated Therapies Market, 2021-2030: Distribution by Target Indication (USD Million)
  • Table 11.51 Light Activated Therapies Market, 2021-2030: Distribution by Key Players (USD Million)
  • Table 11.52 Light Activated Therapies Market, 2021-2030: Distribution by Geography (USD Million)
  • Table 11.53 Cetuximab Sarotalocan® (Rakuten Medical): Sales Forecast, 2021-2030 (USD Million)
  • Table 11.54 Photodynamic Therapy and Alacare® (medec): Sales Forecast, 2021-2030(USD
  • Table 11.55 Photodynamic Therapy and Ameluz® (Biofrontera): Sales Forecast, 2021-2030(USD Million)
  • Table 11.56 Photodynamic Therapy and Aminolevulinic Acid (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical): Sales Forecast, 2021-2030 (USD Million)
  • Table 11.57 Photodynamic Therapy and Foscan® (Temoporfin) (biolitec Pharma): SalesForecast, 2021-2030 (USD Million)
  • Table 11.58 Photodynamic Therapy and FuMeiDa® (Hemoporfin) (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical): Sales Forecast, 2021-2030 (USD Million)
  • Table 11.59 Photodynamic Therapy and Levulan Kerastick® (Sun Pharmaceuticals): SalesForecast, 2021-2030 (USD Million)
  • Table 11.60 Photodynamic Therapy and Metvixia® (Metvix) (Galderma): Sales Forecast,2021-2030 (USD Million)
  • Table 11.61 Photodynamic Therapy and Porfimer Sodium / Photofrin® (ADVANZPHARMA): Sales Forecast, 2021-2030 (USD Million)
  • Table 11.62 Photodynamic Therapy and Verteporfin® (Visudyne) (Novartis): SalesForecast, 2021-2030 (USD Million)
  • Table 11.63 Photodynamic Therapy and TLD-1433 (Theralase): Sales Forecast, 2021-2030(USD Million)
  • Table 11.64 Photodynamic Therapy and TOOKAD® VTP (Steba biotech): Sales Forecast, World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

  • 1. Ac BioScience
  • 2. Academic Medical Center (Academisch Medisch Centrum)
  • 3. Acclarent
  • 4. Accovion (acquired by Clinipace)
  • 5. ADVANZ PHARMA
  • 6. Association for Innovation and Biomedical Research on Light and Image (AIBILI)
  • 7. AinA
  • 8. Alcon
  • 9. Alexandria University
  • 10. Alpheus Medical
  • 11. Ambalal Sarabhai Enterprises
  • 12. American Society for Gastrointestinal Endoscopy
  • 13. Amgen
  • 14. An Hui Angkefeng Optoelectronic Technology
  • 15. Anhui University
  • 16. Asan Medical Center
  • 17. Ascend Biopharmaceuticals
  • 18. Association of Paediatric and Preventive Dentists of Serbia
  • 19. Association to Prevent Blindness in Mexico
  • 20. AstraZeneca
  • 21. Autonomous University of Madrid
  • 22. Axcan Pharma
  • 23. Azienda Ospedaliero Universitaria Pisana (AOUP)
  • 24. Barnes Retina Institute
  • 25. Barretos Cancer Hospital
  • 26. Bascom Palmer Eye Institute
  • 27. Bausch + Lomb
  • 28. Bausch Health
  • 29. Bay Area Retina Associates
  • 30. Bayer
  • 31. Beckman Laser Institute & Medical Clinic
  • 32. BeiJing Fullcan Biotechnology
  • 33. Beijing Institute of Technology
  • 34. Beijing University of Chemical Technology
  • 35. Biodynamic Association (BDA)
  • 36. Biofrontera
  • 37. biolitec Pharma
  • 38. BioVentures
  • 39. Bispebjerg Hospital
  • 40. Boehringer Ingelheim
  • 41. Brigham and Women's Hospital
  • 42. Bristol-Myers Squibb
  • 43. Cairo University
  • 44. California Retina Consultants
  • 45. Canadian Cancer Trials Group (CCTG)
  • 46. Carol Davila University of Medicine and Pharmacy
  • 47. Case Comprehensive Cancer Center
  • 48. Case Western Reserve University
  • 49. Celgene
  • 50. Cellvizio
  • 51. Central Norway Regional Health Authority
  • 52. Central South University
  • 53. CeramOptec
  • 54. CEU Cardenal Herrera University
  • 55. Changchun Institute of Applied Chemistry
  • 56. Chimie ParisTech - PSL
  • 57. China Medical University
  • 58. China Pharmaceutical University
  • 59. Chinese Academy of Medical Sciences
  • 60. Chinese Academy of Tropical Agricultural Sciences
  • 61. Chinese PLA General Hospital
  • 62. Chinese University of Hong Kong
  • 63. Chongqing Medical University
  • 64. Chonnam National University Hospital
  • 65. Chu De Lille
  • 66. Chulalongkorn University
  • 67. Clinica Universidad de Navarra
  • 68. Clinuvel Pharmaceuticals
  • 69. CMS Dental
  • 70. Complutense University of Madrid
  • 71. Concordia Laboratories
  • 72. Coralluma
  • 73. CorePharma
  • 74. Cornell University
  • 75. CosmoPHOS-nano
  • 76. CranioVation
  • 77. DR Nano
  • 78. Dalian University of Technology
  • 79. Dartmouth College
  • 80. Dartmouth-Hitchcock Medical Center
  • 81. De Haar Research Foundation (DHRF)
  • 82. Dermatology, Laser & Vein Specialists of the Carolinas
  • 83. Dermira
  • 84. Dong-A University
  • 85. Duke University
  • 86. DUSA Pharmaceuticals
  • 87. Eastern Cooperative Oncology Group (ECOG)
  • 88. Eastern Liaoning University
  • 89. Eastern Virginia Medical School
  • 90. Eastern Virginia Medical School Foundation (EVMS)
  • 91. Ecatepec Medical Center
  • 92. Eisai
  • 93. Eli Lilly and Company
  • 94. Emory University
  • 95. Erasmus University Medical Center
  • 96. European Commission
  • 97. European Vision Clinical Research (EVICR)
  • 98. Faculdade de Medicina do ABC
  • 99. Fluminense Federal University (UFF)
  • 100. First Affiliated Hospital of Kunming Medical University
  • 101. First Moscow State Medical University
  • 102. Foundation Medicine
  • 103. Fourth Military Medical University
  • 104. Fraunhofer Society
  • 105. Fudan University
  • 106. Fujian Longhua Pharmaceutical
  • 107. Fujian Medical University
  • 108. Fujifilm
  • 109. Fuzhou University
  • 110. Galderma
  • 111. Genentech
  • 112. General Hospital of Ningxia Medical University
  • 113. George Washington University
  • 114. German Cancer Aid
  • 115. German Cancer Research Center
  • 116. GlaxoSmithKline
  • 117. Guangzhou Medical University
  • 118. Guilin University of Electronic Technology
  • 119. Guiyang College of Traditional Chinese Medicine
  • 120. Gwangju Institute of Science and Technology
  • 121. Hadassah Medical Center
  • 122. Hallym University Medical Center
  • 123. Harbin Institute of Technology
  • 124. Hasselt University
  • 125. Haukeland University Hospital
  • 126. Henan Provincial People's Hospital
  • 127. Henan University of Science and Technology
  • 128. Hepatopancreatobiliary Surgery Institute of Gansu Province
  • 129. Hisun Pharmaceutical
  • 130. Hong Kong Baptist University
  • 131. Hong Kong University of Science and Technology
  • 132. Hospital Erasme
  • 133. Hospital of Southern Norway
  • 134. Hospital of the Johann Wolfgang Goethe University
  • 135. Hospital Pérola Byington
  • 136. Huadong Hospital Affiliated to Fudan University
  • 137. HUS Helsinki University Hospital
  • 138. Illinois Retina Associates
  • 139. Indiana University
  • 140. Innovaderm Research
  • 141. Inova
  • 142. Institut National de la Sante et de la Recherche Medicale (Inserm)
  • 143. Institute of Chemistry Chinese Academy of Sciences
  • 144. Institute of Clinical and Experimental Medicine
  • 145. Ipsen
  • 146. IQVIA
  • 147. Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS)
  • 148. Janssen
  • 149. Jawaharlal Nehru Medical College
  • 150. Jessa Hospital
  • 151. Jewish General Hospital
  • 152. Jiangnan University
  • 153. Jilin Institute of Chemical Technology
  • 154. Johns Hopkins University
  • 155. Kafrelsheikh University
  • 156. Kiadis Pharma
  • 157. Kim's Eye Hospital
  • 158. King Chulalongkorn Memorial Hospital
  • 159. King Fahd University of Petroleum and Minerals
  • 160. King Saud University
  • 161. KLE Society's Institute of Dental Sciences
  • 162. Korea Institute of Science and Technology (KIST)
  • 163. Korea Photonics Technology Institute
  • 164. Kumamoto University
  • 165. Kyung Hee University
  • 166. Laser & Skin Surgery Center of New York
  • 167. Lawson Health Research Institute
  • 168. Leiden University Medical Center
  • 169. LEO Pharma
  • 170. LifePhotonic
  • 171. Light Sciences Oncology
  • 172. Lithuanian University of Health Sciences
  • 173. Liuzhou Workers Hospital
  • 174. Loma Linda University
  • 175. Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
  • 176. Luzitin
  • 177. MD Anderson Cancer Center
  • 178. Maisonneuve-Rosemont Hospital
  • 179. Marmara University
  • 180. Massachusetts General Hospital
  • 181. Mauna Kea Technologies
  • 182. Mayo Clinic
  • 183. McGill University Health Centre
  • 184. medac
  • 185. Medelis
  • 186. Medical College of Wisconsin
  • 187. Medical University of Vienna
  • 188. Mediland Enterprise
  • 189. Medpace
  • 190. Memorial Sloan Kettering Cancer Center
  • 191. Merck
  • 192. Michigan State University
  • 193. Mid Atlantic Retina
  • 194. Miravant Pharmaceuticals
  • 195. Mundipharma Research
  • 196. Munster University Hospital (UKM)
  • 197. Nagoya City University
  • 198. Nanfang Hospital
  • 199. Nanjing Jiangning Hospital
  • 200. Nanjing University of Posts and Telecommunications
  • 201. Nanospectra Biosciences
  • 202. National Cancer Institute
  • 203. National Center for Research Resources
  • 204. National Center for Tumor Diseases (NCT)
  • 205. National Chung Hsing University
  • 206. National Eye Institute
  • 207. National Institutes of Health (NIH)
  • 208. National Taiwan University
  • 209. National University Hospital
  • 210. National University of Singapore
  • 211. NeoMedLight
  • 212. New England Retina Associates
  • 213. Nihon University Hospital
  • 214. Nordland Hospital Trust
  • 215. Norris Cotton Cancer Center
  • 216. North Carolina State University
  • 217. North Florida Foundation for Research and Education
  • 218. Northwestern Polytechnical University
  • 219. Northwestern University
  • 220. Norwegian University of Science and Technology
  • 221. Nova Scotia Health Authority
  • 222. Novartis
  • 223. NYU College of Dentistry
  • 224. Oklahoma State University Center for Health Sciences
  • 225. On Target Laboratories
  • 226. Ondine Biomedical
  • 227. Ondine Biopharma
  • 228. Oregon Health and Science University
  • 229. Osaka University
  • 230. OSHU Knight Cancer Institute
  • 231. Oslo University Hospital
  • 232. Ostfold Hospital Trust
  • 233. Otsuka Electronics
  • 234. Pacific Derm
  • 235. Paderborn University
  • 236. Peking University
  • 237. Peking University People's Hospital
  • 238. Peking University School of Stomatology
  • 239. Pfizer
  • 240. Pharma Power Biotec
  • 241. Photocure
  • 242. photonamic
  • 243. Pinnacle Biologics
  • 244. Poitiers University Hospital
  • 245. Pontifical Catholic University
  • 246. PrimeVigilance
  • 247. Privolzhsky Research Medical University
  • 248. PSL Research University
  • 249. Purdue Research Foundation
  • 250. Qingdao University
  • 251. QLT
  • 252. Radboud University
  • 253. Rakuten Medical
  • 254. Rapid Labs
  • 255. Regeneron Pharmaceuticals
  • 256. Renji Hospital
  • 257. Republic Polytechnic
  • 258. Retinal Consultants Medical
  • 259. Rhode Island Hospital
  • 260. RMW Cho Group
  • 261. Roche
  • 262. Rogers Sciences
  • 263. Rosalind Franklin University of Medicine and Science
  • 264. Roswell Park Cancer Institute
  • 265. Rothman Orthopaedic Institute
  • 266. Ruhr University-Bochum
  • 267. RWTH Aachen University
  • 268. Salt & Light Pharmaceuticals
  • 269. Samsung Medical Center
  • 270. São Paulo Research Foundation (FAPESP)
  • 271. SBI Pharmaceuticals
  • 272. Seoul National University Bundang Hospital
  • 273. Seoul St. Mary's Hospital
  • 274. Shahid Beheshti University of Medical Sciences
  • 275. Shanghai Dermatology Hospital
  • 276. Shanghai First People's Hospital North Branch
  • 277. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • 278. Shanghai General Hospital
  • 279. Shanghai Jiao Tong University School of Medicine
  • 280. Sharp
  • 281. Sheffield Teaching Hospitals NHS Foundation Trust
  • 282. Shenzhen Hanguang Technology
  • 283. Shenzhen Institute of Advanced Technology
  • 284. Shenzhen Institute of Information Technology
  • 285. Shenzhen International Institute for Biomedical Research
  • 286. Shimadzu
  • 287. Shin Kong Wu Ho-Su Memorial Hospital
  • 288. Sichuan Provincial People's Hospital
  • 289. Sidney Kimmel Comprehensive Cancer Center
  • 290. Singapore National Eye Centre
  • 291. South China University of Technology
  • 292. Southeast University
  • 293. Southern Illinois University
  • 294. Southern University of Science and Technology
  • 295. Spanish National Research Council
  • 296. SpectraCure
  • 297. St. Jude Children's Research Hospital
  • 298. St. Olav's University Hospital
  • 299. St. Vincent's Private Hospital
  • 300. Stand Up To Cancer
  • 301. Stanford University
  • 302. Steba biotech
  • 303. Sun Pharma
  • 304. Sun Yat-sen University
  • 305. Sunnybrook Health Sciences Centre
  • 306. Suzhou Hvha Medical Technology
  • 307. SVS Institute of Dental Sciences
  • 308. Swiss National Science Foundation (SNSF)
  • 309. Tampere University
  • 310. Tan Tock Seng Hospital
  • 311. Taoyuan General Hospital, Ministry of HealthTeikyo University
  • 312. The Affiliated Hospital of Xuzhou Medical University
  • 313. Tel Aviv Sourasky Medical Center
  • 314. Texas Retina Associates
  • 315. The Catholic University of America
  • 316. The Cleveland Clinic
  • 317. The Colorado Health Foundation
  • 318. The First Affiliated Hospital of Xinjiang Medical University
  • 319. The First Affiliated Hospital with Nanjing Medical University
  • 320. The Lowy Medical Research Institute
  • 321. The Netherlands Cancer Institute
  • 322. The Regents of the University of Michigan
  • 323. The Second Affiliated Hospital of Xi'an Jiaotong University
  • 324. The Second Xiangya Hospital of Central South University
  • 325. The Third Xiangya Hospital of Central South University
  • 326. The University of Texas at Austin
  • 327. The First Affiliated Hospital of Xi'an Jiaotong University
  • 328. Theralase Technologies
  • 329. Tokyo Institute of Technology
  • 330. Tongji University
  • 331. Tripler Army Medical Center
  • 332. Tsinghua University
  • 333. Tufts Medical Center
  • 334. UCB Pharma
  • 335. UCSF Benioff Children Hospital
  • 336. University College Cardiff Consultants
  • 337. University College Hospital
  • 338. University College London
  • 339. University Health Network
  • 340. University Hospital Heidelberg
  • 341. University Hospital of North Norway
  • 342. University Hospital Regensburg
  • 343. University Hospitals Cleveland Medical Center
  • 344. University Institute of Applied Ophthalmobiology (IOBA)
  • 345. University of Alabama at Birmingham
  • 346. University of Arizona
  • 347. University of British Columbia
  • 348. University of California Irvine
  • 349. University of Coimbra
  • 350. University of Cologne
  • 351. University of Dundee
  • 352. University of Exeter
  • 353. University of Georgia
  • 354. University of Hamburg
  • 355. University of Kansas
  • 356. University of Kansas Medical Center
  • 357. University of Jyväskylä
  • 358. University of La Frontera
  • 359. University of Lille
  • 360. University of Lodz
  • 361. University of Manitoba
  • 362. University of Massachusetts
  • 363. University of Miami
  • 364. University of Michigan
  • 365. University of Münster
  • 366. University Of Mysore (UoM)
  • 367. University of Navarra
  • 368. Universidade Nove de Julho
  • 369. University of Oxford
  • 370. University of Padua
  • 371. University of Pennsylvania
  • 372. University of Regensburg
  • 373. University of Rochester
  • 374. University of Salzburg
  • 375. University of South Carolina
  • 376. University of South Florida
  • 377. University of Toronto
  • 378. University of Washington
  • 379. University of Wisconsin
  • 380. University of Zurich
  • 381. Ural Federal University
  • 382. Ural Institute of Cardiology
  • 383. USHEALTH Group
  • 384. Vaasa Central Hospital
  • 385. Vestre Viken Hospital Trust
  • 386. VieCuri Medical Center
  • 387. Vienna Institute for Research In Ocular Surgery
  • 388. Wake Forest University Health Sciences
  • 389. WCCT Global
  • 390. Weill Medical College of Cornell University
  • 391. Weizmann Institute of Science
  • 392. Wenzhou Jingyu Medical Instruments
  • 393. Wenzhou Medical College Affiliated Yanshiguang Hospital
  • 394. Wenzhou Medical University
  • 395. West China Hospital
  • 396. Wright State Physicians
  • 397. Wuhan Institute of Technology
  • 398. Xidian University
  • 399. Xinjiang Medical University
  • 400. Xuzhou Medical University
  • 401. Zhejiang Hisun Pharmaceutical
  • 402. Zhejiang University
  • 403. Zhejiang University of Science and Technology
  • 404. Zhongshan Hospital Xiamen University
  • 405. Zhuhai People's Hospital
  • 406. Zimmer BioTech
  • 407. Zimmer MedizinSysteme
  • 408. Zonguldak Bulent Ecevit University